Aberrant Regulation of DNA Methylation in Amyotrophic Lateral Sclerosis: A New Target of Disease Mechanisms

Neurotherapeutics

Volumn 10, Issue 4, 2013, Pages 722-733

  Martin, Lee J ^a   Wong, Margaret ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 methylcytosine; Chromatin modification; DNA methyltransferase; mitochondria; motor neuron; RG108

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 AZA CYTIDINE; 5 METHYLCYTOSINE; ANTIBIOTIC AGENT; CYCLIC GMP; CYTIDINE DERIVATIVE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE INHIBITOR; HYDRALAZINE; N PHTHALOYLTRYPTOPHAN; PROCAINAMIDE; PSAMMAPLIN; UNCLASSIFIED DRUG; ZEBULARINE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BIOACCUMULATION; CANCER CHEMOTHERAPY; CATALYSIS; CELL PROTECTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; CLONOGENESIS; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG INHIBITION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE CONTROL; GENETIC ANALYSIS; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL CULTURE; HYPERTENSION; INTERNEURON; LUPUS LIKE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MOTONEURON; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PLEIOTROPY; PRECANCER; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SKELETAL MUSCLE; TUMOR CELL LINE; VASODILATATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DNA METHYLATION; HUMANS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NERVE DEGENERATION;

EID: 84886293196     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0205-6     Document Type: Review

References (121)

1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Eng J Med 2001;344: 1688-1700.
2. Zoccolella S, Santamato A, Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat 2009;5: 577-595.
3. Eisen A. Amyotrophic lateral sclerosis: a 40-year personal perspective. J Clin Neurosci 2009;16: 505-512.
4. Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002;26: 438-458.
5. Martin LJ. Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals 2010;3: 839-915.
6. Martin LJ. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010;13: 568-580.
7. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362: 59-62.
8. Morris HR, Waite AJ, Williams NM, Neal JW, Blake DJ. Recent advances in the genetics of the ALS-FTLD complex. Curr Neurol Neurosci 2012;12: 243-250.
9. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72: 257-268.
10. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683-692.
11. Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010;81: 1324-1326.
12. Fraga M, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Nat Acad Sci 2005;102: 10604-10609.
13. Schymick JC, Talbot K, Traynor BJ. Genetics of sporadic amyotrophic lateral sclerosis Hum Mol Gen 2007;16: R233-R242.
14. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008;85: 94-134.
15. Redler RL, Dokholyan NV. The complex molecular biology of amyotrophic lateral sclerosis. Prog Mol Biol Trans Sci 2012;107: 215-262.
16. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006;52: 39-59.
17. Qureshi IA, Mehler ME. Advances in epigenetics and epigenomics for neurodegenerative diseases. Curr Neurol Neurosci Rep 2011;11: 464-473.
18. Wolffe AP, Matzke MA. Epigenetics: Regulation through repression. Science 1999;286: 481-486.
19. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl.): 245-254.
20. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13: 484-492.
21. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999;98: 285-294.
22. Levenson JM, Roth TL, Lubin FD, et al. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem 2006;281: 15763-15773.
23. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol 2002;22: 3157-3173.
24. Yang X, Yan, L, Davidson N. DNA methylation in breast cancer. Endocr Relat Cancer 2001;8: 115-127.
25. Luczak MW, Jagodzinski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol 2006;44: 143-154.
26. Cheng X. Structure and function of DNA methyltransferases. Ann Rev Biophys Biomol Struct 1995;24: 293-318.
27. Pradhan S, Bacolla A, Wells RD, Roberts RJ. Recombinant human DNA (cytosine-5) methyltransferase I: expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 1999;274: 33002-33010.
28. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000;9: 2395-2402.
29. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmcol Toxicol 2009;49: 243-263.
30. Mazin AL. Suicidal function of DNA methylation in age-related genome disintegration. Ageing Res Rev 2009;8: 314-327.
31. Brenner C, Fuks F. DNA methyltransferases: Facts, clues, mysteries. Curr Top Microbiol Immunol 2006;301: 45-66.
32. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16: 6-21.
33. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196: 261-282.
34. Fatemi M, Pao M, Jeong S, et al. Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res 2005;33: e176.
35. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001;293: 1068-1070.
36. Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 2003;278: 4806-4812.
37. Varley KE, Gertz J, Bowling KM, et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res 2013;23: 555-567.
38. Barres R, Osler ME, Yan J, et al. Non-CpG methylation of the PGP-1α promoter through DNMT3B controls mitochondrial density. Cell Metab 2009;10: 189-198.
39. Ziller MJ, Muller F, Liao J, et al. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet 2001;7: e1002389.
40. Maunakea AK, Nagarajan RP, Bilenky M, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010;466: 253-260.
41. Wu H, Coskun V, Tao J, et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 2010;329: 444-448.
42. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons in the brain. Science 2009;324: 929-930.
43. Tahiliani M, Koh, KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylytosine in mammalian DNA by MLL partner TET1. Science 2009;324: 930-935.
44. Jin S-G, Wu X, Li A, Pfeifer GP. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nuc Acids Res 2011;39: 5015-5024.
45. Wu SC, Zhang Y. Active DNA methylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010;11: 607-620.
46. Globisch D, Münzel M, Müller M, et al. Tissue distribution of 5-hydroxymethlycytosine and search for active demethylation intermediates. PLoS One 2010;5: e15367.
47. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20: 31-39.
48. Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt H. Recruitment of DNA methyltransferase I to DNA repair sites. Proc Natl Acad Sci USA 2005;102: 8905-8909.
49. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to from a complex at replication foci. Nature Genet 2000;24: 269-277.
50. Espada J. Non-catalytic functions of DNMT1. Epigenetics 2012;7: 115-118.
51. Schaefer M, Lyko F. Solving the Dnmt2 enigma. Chromosoma 2010;119: 35-40.
52. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99: 247-257.
53. Xie S, Wang Z, Okano M, Nogami M, Li Y, He WW, Okumura K, Li E. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene 1999; 236: 87-95.
54. Kangaspeska S, Stride B, Métivier R, et al. Transient cyclical methylation of promoter DNA. Nature 2008;452: 112-115.
55. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007;449: 248-251.
56. Hansen RS, Wijmenga C, Luo P, et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 1999;96: 14412-14417.
57. Klein CJ, Botuyan M-V, Wu Y, et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet 2011;43: 595-600.
58. Winkelman J, Lin L, Schormair B, et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet 2012;21: 2205-2210.
59. Easwaran HP, Schermelleh L, Leonhardt H, Cardoso MC. Replication-independent chromatin loading of Dnmt1 during G2 and M phases. EMBO Rep 2004;5: 1181-1186.
60. Martinowich K, Hattori D, Wu H, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003;302: 890-893.
61. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 2001;69: 915-926.
62. Endres M, Meisel A, Biniskiewicz D, et al. DNA methyltransferase contributes to delayed ischemia brain injury J Neurosci 2000;20: 3175-3181.
63. Fan G, Beard C, Chen RZ, et al. DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J Neurosci 2001;21: 788-797.
64. Hutnick LK, Golshani P, Namihira M, et al. DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. Hum Mol Genet 2009;18: 2875-2888.
65. Nguyen S, Meletis K, Fu D, Jhaveri S, Jaenisch R. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened life span. Dev Dyn 2007;236: 1663-1676.
66. Goto K, Numata M, Komura JI, et al. Expression of DNA methyltransferase gene in mature and immature neurons as well as proliferating cells in mice. Differentiation 1994;56: 39-44.
67. Brooks PJ, Marietta C, Goldman D. DNA mismatch repair and DNA methylation in adult brain neurons. J Neurosci 1996;16: 939-945.
68. Inano K, Suetake I, Ueda T, et al. Maintenance-type DNA methyltransferases is highly expressed in post-mitotic neurons and localized in the cytoplasmic compartment. J Biochem 2000;128: 315-321.
69. Feng J, Chang H, Li E, Fan G. Dynamic expression of de novo DNA methyltransferase DNMT3A and DNMT3B in the central nervous system. J Neurosci Res 2005;79: 734-746.
70. Chestnut BA, Chang Q, Price A, Lesuisse C, Wong M, Martin LJ. Epigenetic regulation of motor neuron cell death through DNA methylation. J Neurosci 2011;31: 16619-16636.
71. Miller CA, Sweatt JD. Covalent modification of DNA regulates memory formation. Neuron 2007;53: 857-869.
72. LaPlant Q, Vialou V, Covington HE 3rd, et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci 2010;13: 1137-1143.
73. Feng J, Zhou Y, Campbell SL, et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci 2010;13: 423-30.
74. Shock LS, Thakkar PV, Peterson EJ, Moran RG, Taylor SM. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc Natl Acad Sci U S A 2011;108: 3630-3635.
75. Shmookler Reis RJ, Goldstein S. Mitochondrial DNA in mortal and immortal cells: Genome number, integrity, and methylation. J Biol Chem 258: 1983;9078-9085.
76. Pollack Y, Kasir J, Shemer R, Metzger S, Szyf M. Methylation pattern of mouse mitochondrial DNA. Nucleic Acids Res 1984;12: 4811-4824.
77. Oates N, Pamphlett R. An epigenetic analysis of SOD1 and VEGF in ALS. Amyotroph Lateral Scler 2007;8: 83-86.
78. Morahan JM, Yu B, Trent RJ, Pamphlett R. Are metallothionein genes silenced in ALS? Toxicol Lett 2007;168: 83-87.
79. Yang Y, Gozen O, Vidensky S, Robinson MB, Rothstein JD. Epigenetic regulation of neuron-dependent induction of astroglial synaptic protein GLT1. Glia 2010;58: 277-286.
80. Morahan JM, Yu B, Trent RJ, Pamphlett R. A genome-wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10: 418-429.
81. Ladd-Acosta C, Pevsner J, Sabunciyan S, et al. DNA methylation signatures within the human brain. Am J Hum Genet 2007;81: 1304-1315.
82. Nishioka M, Shimada T, Bundo M, et al. Neuronal cell-type specific DNA methylation patterns of the Cacna1 gene. Int J Devl Neurosci 2013;31: 89-95.
83. Figueroa-Romero C, Hur J, Bender DE, et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS ONE 2012;7: e52672.
84. Ginsberg SD, Hemby SE, Mufson EJ, Martin LJ. Cell and tissue microdissection in combination with genomic and proteomic applications. In: Zaborsky L, Wouterlood FG, Lanciego JL (eds) Neuroanatomical tract-tracing 3: molecules, neurons, and systems. Springer, Singapore, 2006, pp. 109-141.
85. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72: 245-256.
86. 2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet 2013;92: 981-989.
87. Hadano S, Hand CK, Osuga H, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001;29: 166-173.
88. Yang Y, Hentati A, Deng HX et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001;29: 160-165.
89. Labonte B, Suderman M, Maussion G, et al. Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry 2012;69: 722-731.
90. Martin LJ, Chen K, Liu Z. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked to DNA damage and p53 activation. J Neurosci 2005; 25: 6449-6459.
91. Martin LJ, Liu Z, Chen K, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 2007;500: 20-46.
92. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999;58: 459-471.
93. Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol Dis 2000;7: 613-622.
94. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65: 6305-6311.
95. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005;280: 40749-40756.
96. Santourlidis S, Kimura F, Fischer J, Schulz WA. Suppression of clonogenicity by mammalian Dnmt1 mediated by the PCNA-binding domain. Biochem Cell Biol 2004;82: 589-596.
97. Li HL, Ma AN. Induction of apoptosis of non-small cell lung cancer by a methylated oligonucleotide targeting surviving gene. Cancer Gene Therapy 2010;17: 441-446.
98. Tolosa L, Mir M, Asensio VJ, et al. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem 2008;105: 1080-1090.
99. Narayan A, Tuck-Muller C, Weissbecker K, et al. Hypersensitivity to radiation-induced non-apoptotic and apoptotic death in cell lines from patients with the ICF chromosome instability syndrome. Mut Res 2000;456: 1-15.
100. Metivier R, Gallais R, Tiffoche C, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008;452;45-50.
101. Nelson ED, Kavalali ET, Monteggia LM. Activity-dependent suppression of miniature neurotransmission through the regulation of DNA methylation. J Neurosci 2008;28: 395-406.
102. Chang Q, Martin LJ. Glycine receptor channels in spinal motoneurons are abnormal in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2011;31: 2815-2827.
103. Chang Q, Martin LJ. Glycinergic Innervation of motoneurons is deficient in amyotrophic lateral sclerosis mice: a confocal quantitative analysis. Am J Path 2009;174: 574-585.
104. Martin LJ, Chang Q. Inhibitory synaptic regulation of motoneurons: a new target of disease mechanisms in ALS. Mol Neurobiol 2012;45: 30-42.
105. McGown A, McDearmid JR, Panagiotaki N, et al. Early interneuron dysfunction in ALS: Insights from a mutant sod1 zebrafish model. Ann Neurol 2001;73: 246-258.
106. Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in ALS? Amyotroph Lateral Scler 2012;13: 245-250.
107. Matrisciano F, Tueting P, Dalal I, et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 2013;68: 184-194.
108. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002;26: 459-470.
109. Harwood CA, McDermott CJ, Shaw PJ. Physical activity as an exogenous risk factor in motor neuron disease (MND): A review of the evidence. Amyotroph Lateral Scler 2009;10: 191-204.
110. Huisman MHB, Seelen M, de Jong SW, et al. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013. doi: 10. 1136/jnnp-2012-304724.
111. Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011;10: 75-82.
112. Ribel-Madsen R, Fraga MF, Jacobsen S, et al. Genome-wide analysis of DNA methylation differences in muscle and fat from monozygotic twins discordant for type 2 diabetes. PLoS ONE 2012;7: e51302.
113. Wong M, Martin LJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet 2010;19: 2284-2302.
114. Vielhaber S, Winkler K, Kirches E, et al. Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 1999;169: 133-139.
115. Echaniz-Laguna A, Zoll J, Ponsot E, et al. Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: A temporal study in man. Exp Neurol 2006;198: 25-30.
116. Pradat P-F, Barani A, Wanschitz J, et al. Abnormalities of satellite cells function in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12: 264-271.
117. Donoghue MJ, Sanes JR. All muscles are not created equal. Trends Genet 1994;10: 396-401.
118. Coffey AG, Hawley JA. The molecular bases of training adaptation. Sports Med 2007;37: 737-763.
119. Barrès R, Yan J, Egan B, et al. Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab 2012;15: 405-411.
120. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with 'epigenetic' drugs: an update. Mol Oncol 2012;6: 657-682.
121. Baar K. Epigenetic control of skeletal muscle fiber type. Acta Physiol 2010;199: 477-487.